Sarepta Therapeutics (SRPT)
(Delayed Data from NSDQ)
$122.84 USD
-2.16 (-1.73%)
Updated Jun 14, 2024 04:00 PM ET
After-Market: $122.86 +0.02 (0.02%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth A Momentum D VGM
Brokerage Reports
Sarepta Therapeutics, Inc. [SRPT]
Reports for Purchase
Showing records 621 - 640 ( 661 total )
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
LIFE SCIENCES-The Week Ahead in Life Sciences - Upcoming Events for the Week of May 20
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of May 13
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
LIFE SCIENCES-The Week Ahead in Life Sciences - Upcoming Events for the Week of May 6
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
EOP2 Meeting Minutes Suggest FDA Potentially Open to Accelerated Filing - Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: MARAI C
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
World Orphan Drug Congress Insights Suggest Accelerated Approval Filing Likely - Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: MARAI C
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Prosensa''s Data Promising, but Lacks Key Safety Details and Highlights the Limitations of Clinical Data for Exon-Skipping Approaches in DMD
Provider: WEDBUSH SECURITIES INC.
Analyst: MARAI C
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of April 8
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Eteplirsen Data at 74 Weeks Continues to Support Clinically Meaningful Benefit and Safety
Provider: WEDBUSH SECURITIES INC.
Analyst: MARAI C
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
LIFE SCIENCES-The Week Ahead in Life Sciences - Upcoming Events for the Week of March 18
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Q4:12 Results - Mid-Scale Manufacturing Scale-Up Complete - Next Up, End of Phase II Meeting Update and 74- Week Data - Reiterate Outperform
Provider: WEDBUSH SECURITIES INC.
Analyst: MARAI C
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of March 4
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
End of Phase 2 FDA Meeting Update May Occur Sooner Than Expected Creating a Buying Opportunity and a Shift in Focus to SRPT''s Risk-Reduced Pipeline
Provider: WEDBUSH SECURITIES INC.
Analyst: MARAI C
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
We are terminating research coverage due to the termination or loss of the primary and/or secondary analysts responsible for coverage.
Provider: DAWSON JAMES SECURITIES, INC.
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Pipeline Remains Undervalued as Follow-on Compounds Could Launch Along Side Eteplirsen
Provider: WEDBUSH SECURITIES INC.
Analyst: MARAI C
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Pipeline Remains Undervalued as Follow-on Compounds Could Launch Along Side Eteplirsen; Updating Price Target Due To Financing - Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: MARAI C
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
LIFE SCIENCES - The Week Ahead in Life Sciences - Upcoming Events for the Week of January 6
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Q3:12 Results - Awaiting Details of the End of Phase II
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Expert Call Highlights - Eteplirsen''s "Impressive" Clinical Benefit "Very Promising"
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
TODAY: Expert Conference Call with Dr. Craig M. McDonald, M.D. on Duchenne Muscular Dystrophy Disease Progression and Clinical Endpoints.
Provider: WEDBUSH SECURITIES INC.
Analyst: WADE G